文献速递胸部肿瘤

内脏性肥胖促进肺癌进展:迈向解决肺癌肥胖悖论

Visceral Obesity Promotes Lung Cancer Progression-Toward Resolution of the Obesity Paradox in Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2021-05-25

该研究假设肺癌「肥胖悖论」部分源于用BMI衡量肥胖的局限,采用术前CT量化内脏脂肪指数(VFI),排除二甲双胍使用者后,分析513例I-II期NSCLC肺叶切除患者的预后,发现高VFI与无复发生存和总生存下降相关,并与肿瘤炎症转录签名负相关,动物模型亦支持内脏肥胖促进肿瘤进展。

要点

  • 高内脏脂肪指数与I-II期NSCLC术后无复发生存和总生存下降相关。
  • VFI与NSCLC肿瘤炎症转录签名呈负相关。
  • 肥胖悖论可能部分源于BMI测量局限及二甲双胍使用混杂。

核心结论

  • 在多条证据中,内脏性肥胖对NSCLC患者呈不良影响,与动物模型一致。
  • 肺癌肥胖悖论至少部分可能继发于以BMI衡量肥胖及二甲双胍使用的混杂效应。

研究设计与样本

  • 回顾性分析术前CT量化脂肪,以腹部内脏脂肪面积除以总脂肪面积得VFI,排除二甲双胍使用者,探索VFI与I-II期NSCLC手术切除后结局的关联。
  • 纳入513例接受肺叶切除术的I-II期NSCLC患者。
  • 补充分析NSCLC肿瘤基因表达数据及饮食诱导肥胖的免疫健全小鼠肺癌模型的肿瘤转录组与免疫微环境。

主要发现

  • 在513例I-II期NSCLC肺叶切除患者中,高VFI与无复发生存和总生存下降相关。
  • VFI与NSCLC肿瘤中的炎症转录组签名呈负相关。
  • 在免疫健全小鼠模型中,饮食诱导肥胖促进癌症进展并加剧肿瘤微环境的免疫抑制要素。

临床怎么用

  • 对I-II期NSCLC术后患者,可考虑以CT量化的VFI而非仅BMI评估肥胖相关风险。
  • 评估肥胖对肺癌预后影响时需注意二甲双胍使用等混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Although obesity is associated with adverse cancer outcomes in general, most retrospective clinical studies suggest a beneficial effect of obesity in NSCLC. METHODS: Hypothesizing that this "obesity paradox" arises partly from the limitations of using body mass index (BMI) to measure obesity, we quantified adiposity using preoperative computed tomography images. This allowed the specific determination of central obesity as abdominal visceral fat area normalized to total fat area (visceral fat index [VFI]). In addition, owing to the previously reported salutary effect of metformin on high-BMI patients with lung cancer, metformin users were excluded. We then explored associations between visceral obesity and outcomes after surgical resection of stage I and II NSCLC. We also explored potential immunologic underpinnings of such association using complimentary analyses of tumor gene expression data from NSCLC tumors and the tumor transcriptome and immune microenvironment in an immunocompetent model of lung cancer with diet-induced obesity. RESULTS: We found that in 513 patients with stage I and II NSCLC undergoing lobectomy, a high VFI is associated with decreased recurrence-free and overall survival. VFI was also inversely related to an inflammatory transcriptomic signature in NSCLC tumors, consistent with observations made in immunocompetent murine models wherein diet-induced obesity promoted cancer progression while exacerbating elements of immune suppression in the tumor niche. CONCLUSIONS: In all, this study uses multiple lines of evidence to reveal the adverse effects of visceral obesity in patients with NSCLC, which align with those found in animal models. Thus, the obesity paradox may, at least in part, be secondary to the use of BMI as a measure of obesity and the confounding effects of metformin use.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Barbi J, Patnaik SK, Pabla S, et al. Visceral Obesity Promotes Lung Cancer Progression-Toward Resolution of the Obesity Paradox in Lung Cancer. J Thorac Oncol. 2021. PMID: 34144926. doi:10.1016/j.jtho.2021.04.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。